50 related articles for article (PubMed ID: 30442506)
1. Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC.
Zhou P; Chen G; Gao M; Wu J
Bioorg Med Chem; 2018 Dec; 26(23-24):6135-6145. PubMed ID: 30442506
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC).
Zhang Y; Tong L; Yan F; Huang P; Zhu CL; Pan C
Bioorg Chem; 2024 Jun; 147():107394. PubMed ID: 38691906
[TBL] [Abstract][Full Text] [Related]
3. Rational design and synthesis of 2,4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFR
Duan L; Chu C; Huang X; Yao H; Wen J; Chen R; Wang C; Tu Y; Lv Q; Pan Q; Xu S
Arch Pharm (Weinheim); 2024 May; 357(5):e2300736. PubMed ID: 38381049
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation.
Zhu Y; Ye X; Wu Y; Shen H; Cai Z; Xia F; Min W; Hou Y; Wang L; Wang X; Xiao Y; Yang P
J Med Chem; 2024 May; 67(9):7283-7300. PubMed ID: 38676656
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor.
Fan D; Zhang H; Duan L; Long L; Xu S; Tu Y; Wang L; Zheng P; Zhu W
Bioorg Chem; 2024 Jun; 147():107390. PubMed ID: 38691904
[TBL] [Abstract][Full Text] [Related]
6. DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun SY
J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38451729
[TBL] [Abstract][Full Text] [Related]
7. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
Uchibori K; Inase N; Araki M; Kamada M; Sato S; Okuno Y; Fujita N; Katayama R
Nat Commun; 2017 Mar; 8():14768. PubMed ID: 28287083
[TBL] [Abstract][Full Text] [Related]
8. Insights into the Overcoming EGFR
Zhang X; He J; Xu S; Fu L; Zheng P; Xu S; Pan Q; Zhu W
ChemMedChem; 2024 May; 19(9):e202300634. PubMed ID: 38351876
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins.
Du Y; Shi S; Shu C; He Y; Xu W; Wu D; Tian Y; Kong M; He J; Xie W; Qiu Y; Xu Y; Zou Y; Zhu Q
Eur J Med Chem; 2024 Jun; 272():116489. PubMed ID: 38759458
[TBL] [Abstract][Full Text] [Related]
11. Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations.
Thomson C; Barton P; Braybrooke E; Colclough N; Dong Z; Evans L; Floc'h N; Guérot C; Hargreaves D; Khurana P; Li S; Li X; Lister A; McCoull W; McWilliams L; Orme JP; Packer MJ; Swaih AM; Ward RA; Winlow P; Ye Y
J Med Chem; 2024 Jun; 67(11):8988-9027. PubMed ID: 38770784
[TBL] [Abstract][Full Text] [Related]
12. A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.
Singh SS; Mattheolabakis G; Gu X; Withers S; Dahal A; Jois S
Eur J Med Chem; 2021 Apr; 216():113312. PubMed ID: 33667849
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of Chemotherapy Efficacy in Cervical Cancer via MAPK Pathway Inhibition by Osimertinib.
Hu Y; Hu C
Cancer Invest; 2024 May; 42(5):425-434. PubMed ID: 38818695
[TBL] [Abstract][Full Text] [Related]
14. Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.
Maciag AE; Nandurdikar RS; Hong SY; Chakrapani H; Diwan B; Morris NL; Shami PJ; Shiao YH; Anderson LM; Keefer LK; Saavedra JE
J Med Chem; 2011 Nov; 54(22):7751-8. PubMed ID: 22003962
[TBL] [Abstract][Full Text] [Related]
15. A novel selenium nanocomposite modified by AANL inhibits tumor growth by upregulating CLK2 in lung cancer.
Zhang Y; Chen Y; Wang B; Cai Y; Zhang M; Guo X; Wu A; Wang W; Liu N; Wang X; Gong Y; Pan J; Jin Y
Bioorg Chem; 2024 Jul; 148():107459. PubMed ID: 38761707
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, characterization, in vitro SAR and in vivo evaluation of N,N'bisnaphthylmethyl 2-alkyl substituted imidazolium salts against NSCLC.
DeBord MA; Southerland MR; Wagers PO; Tiemann KM; Robishaw NK; Whiddon KT; Konopka MC; Tessier CA; Shriver LP; Paruchuri S; Hunstad DA; Panzner MJ; Youngs WJ
Bioorg Med Chem Lett; 2017 Feb; 27(4):764-775. PubMed ID: 28126518
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Potent and Selective Covalent Inhibitors of HER2
Hicken EJ; Brown K; Dwulet NC; Gaudino JJ; Hansen EP; Hartley DP; Kowalski JP; Laird ER; Lazzara NC; Li B; Mou TC; Mutryn MF; Oko L; Pajk S; Pipal RW; Rosen RZ; Shelp R; Singh A; Wang J; Wise CE; Wong C; Wong JY
J Med Chem; 2024 Jun; 67(11):9759-9771. PubMed ID: 38820338
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor as a novel molecular target for aggressive papillary tumors in the middle ear and temporal bone.
Kawabata S; Hollander MC; Munasinghe JP; Brinster LR; Mercado-Matos JR; Li J; Regales L; Pao W; Jänne PA; Wong KK; Butman JA; Lonser RR; Hansen MR; Gurgel RK; Vortmeyer AO; Dennis PA
Oncotarget; 2015 May; 6(13):11357-68. PubMed ID: 26027747
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of 2-(pyridylvinyl)chromen-4-ones and their N-oxide analogs for assessment of their biological activities as anticancer agents.
Ding YC; Chu YC; Chang CH; Liang JH; Chen JJ; Shih TL
Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300445. PubMed ID: 38227420
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy.
Nagano T; Tachihara M; Nishimura Y
Cells; 2018 Nov; 7(11):. PubMed ID: 30445769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
